{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:15:18Z","timestamp":1760285718284,"version":"build-2065373602"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T00:00:00Z","timestamp":1381104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,1,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Lenalidomide is an immunomodulatory drug with effects on the immune system that may enhance antibody\u2010dependent cell\u2010mediated cytotoxicity and reverse tumor\u2010induced immune suppression. Furthermore, single\u2010agent lenalidomide has therapeutic activity in relapsed\/refractory B\u2010cell lymphomas. These immunologic effects potentially may enhance the action of rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>To test the efficacy of lenalidomide combined with rituximab, the authors conducted a phase 2 trial of lenalidomide, low\u2010dose dexamethasone, and rituximab in patients who had rituximab\u2010resistant, relapsed\/refractory, indolent B\u2010cell or mantle cell lymphomas. Patients received two 28\u2010day treatment cycles of lenalidomide 10 mg daily and dexamethasone 8 mg once weekly (part I). During cycle 3, 4 weekly doses of rituximab 375 mg\/m2 were administered with lenalidomide\u2010dexamethasone (part II). After the part II response assessment, stable or responding patients continued to receive lenalidomide\u2010dexamethasone.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twenty\u2010seven patients with follicular (n\u2009=\u200918), mantle cell (n\u2009=\u20095), small lymphocytic (n\u2009=\u20093), and marginal zone (n\u2009=\u20091) lymphomas started therapy; 3 of 27 patients discontinued therapy because of adverse events and were not evaluable for response. For 24 patients, the overall response rate after part I was 29% (4 patients had a complete response [CR] or CR unconfirmed, and 3 patients had a partial response), and the overall response rate after part II was 58% (8 patients had a CR, and 6 patients had a partial response). For 27 patients, at a median follow\u2010up of 12.2 months, the median progression\u2010free survival was 23.7 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The combination of lenalidomide, low\u2010dose dexamethasone, and rituximab achieved high response rates with durable responses in patients with rituximab\u2010resistant, indolent B\u2010cell and mantle cell lymphomas. Overall response rate increased from 29% after two 28\u2010day cycles of lenalidomide and low\u2010dose dexamethasone to 58% after the addition of rituximab, suggesting that lenalidomide can overcome resistance to rituximab. <jats:bold><jats:italic>Cancer<\/jats:italic> 2014;120:222\u2013228<\/jats:bold>. \u00a9 <jats:italic>2013 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28405","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T22:11:56Z","timestamp":1381529516000},"page":"222-228","source":"Crossref","is-referenced-by-count":41,"title":["Combined lenalidomide, low\u2010dose dexamethasone, and rituximab achieves durable responses in rituximab\u2010resistant indolent and mantle cell lymphomas"],"prefix":"10.1002","volume":"120","author":[{"given":"Tahamtan","family":"Ahmadi","sequence":"first","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Gordon","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole A.","family":"Aqui","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony R.","family":"Mato","sequence":"additional","affiliation":[{"name":"Chronic Lymphocytic Leukemia Program, John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Lymphoma Program Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"e_1_2_7_4_1","first-page":"112","article-title":"The impact of rituximab resistance on overall survival rate in low\u2010grade follicular lymphoma [abstract]","author":"Abdollahi S","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"volume-title":"SEER cancer statistics review, 1975\u20102009 (vintage 2009 populations). National Cancer Institute","year":"2012","author":"Howlader N","key":"e_1_2_7_5_1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0577"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21468"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.09.027"},{"volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008","author":"Swerdlow SH","key":"e_1_2_7_16_1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P044"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.95"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.02.001"},{"key":"e_1_2_7_23_1","article-title":"R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed\/refractory indolent non\u2010Hodgkin's lymphoma (NHL) [abstract]","volume":"112","author":"DeRook I","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"e_1_2_7_24_1","article-title":"Lenalidomide plus rituximab leads to a high rate of durable responses in patients with relapsed\/refractory indolent non\u2010Hodgkin's lymphoma [abstract]","volume":"22","author":"Dutia M","year":"2011","journal-title":"Ann Oncol."},{"key":"e_1_2_7_25_1","article-title":"Lenalidomide and rituximab for untreated follicular lymphoma: final results of a phase II study [abstract]","volume":"120","author":"Fowler NH","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28405","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:39:57Z","timestamp":1760283597000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,7]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,1,15]]}},"alternative-id":["10.1002\/cncr.28405"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28405","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2013,10,7]]}}}